About Briacell

Dedicated to enhance the lives of women who are facing limited breast cancer therapy options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering the potential for higher levels of safety and efficacy than chemotherapy and which may prevent cancer recurrence.

Bria-IMT™ (SV-BR-1-GM): Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based technology platform continues to show its impressive potential for treating breast cancer patients. Our lead product candidate, Bria-IMT™ has been shown to stimulate components of the immune system in advanced breast cancer patients. BriaCell maintains rights for Bria-IMT™.

Bria-IMT™ Monotherapy: In a preliminary Phase I clinical study in advanced breast cancer patients who had failed multiple treatments, treatment with Bria-IMT™ significantly reduced tumor size, without serious side effects. Importantly, regression of breast cancer has been observed in other sites including the lung and even the brain -a very difficult site to treat. Impressively, the median lifespan of the patients was substantially longer than anticipated in these advanced breast cancer patients.

The company achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer (ClinicalTrials.gov as NCT03066947). The trial was being conducted along with the co-development of BriaDX™, a companion diagnostic test. Rapid onset of tumor regression was seen especially in patients predicted to be the best responders based on BriaDX™ results.

The ability of Bria-IMT™ to powerfully trigger the immune system to recognize and eliminate cancerous cells is expected to be enhanced when used in combination with multiple immune-modulators.

Collaboration with Incyte Corporation: BriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte’s development portfolio with BriaCell’s drug candidates in advanced breast cancer patients.

BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination Study with the immunotherapy development candidates INCMGA00012, an anti-PD-1 antibody, and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (both provided by Incyte)*. The combination study is listed in ClinicalTrials.gov as NCT03328026.

Combination Study of Bria-IMT™ with KEYTRUDA®*: In 2020, BriaCell announced a Grant to Investigator, Dr. Saveri Bhattacharya, at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™ with KEYTRUDA® [manufactured by Merck & Co., Inc. (NYSE: MRK)] in advanced breast cancer. Merck will provide KEYTRUDA® for use in the Combination Study. For additional information, please directly contact the study coordinator, Ms. Rita Murphy, at Rita.Murphy@jefferson.edu.

Bria-OTS™*: Capitalizing on insights gained with Bria-IMT™ and BriaDX™, BriaCell is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for the treatment for advanced stage breast cancer.

Small Molecule Program: BriaCell’s small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases.

*The continuation and completion of these studies depends on BriaCell securing adequate capital to execute these studies.


  • According to the report published by the American Cancer Society in 2020, approximately 606,520 Americans are expected to die of cancer in 2020 (approximately 1,662 deaths per day), making cancer the second leading cause of death in the US, exceeded only by heart disease.
  • As of January 2020, the number of women with the history of invasive breast cancer is estimated at 3.1 million (excluding the estimated 279,100 new cases in 2020). The number is expected to increase by 12% to 4 million in 2024. Approximately 30% of breast cancers occur in women younger than 50 and 44% occur in women older than 65.
  • According to the facts and figures released by the American Cancer Society in 2020, 276,480 women, and 2,620 men are expected to be diagnosed with invasive breast cancer in 2020 in the US alone. Breast cancer is the most frequently diagnosed cancer in women in the US.
  • Breast cancer deaths in 2020 are estimated at 42,690 (42,170 women, 520 men), making breast cancer the 2nd leading cause of cancer death in women (after lung cancer).
  • As reported by the American Cancer Society in 2020, approximately 62% of breast cancer is detected in early stages (i.e., the cancer is found in the breast tissue, and has not spread to lymph nodes or other regions of the body), for which the 5-year survival rate is estimated at 99%. As soon as the cancer spreads to lymph nodes under the arm or nearby tissues (regional stage), the 5-year survival rate drops to 85%. However, once the cancer spreads to other lymph nodes or body parts {distant stage or metastatic (met-uh-STAT-ic) cancer}, the five-year survival rate falls to as low as 27% (i.e. 73% of the patients die within 5 years). This shows the grave need for effective treatments for this deadly cancer.